A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I...

Area of Science:

• Oncology
• Pharmacology
• Endocrinology

Background:

• Mammary tumors in Sprague-Dawley (SD) rats can be induced by 7, 12-dimethylbenz[a]anthracene (DMBA).
• Aromatase inhibitors are crucial in managing hormone-dependent cancers.
• Vorozole is a potent and specific non-steroidal aromatase inhibitor.

Purpose of the Study:

• To evaluate the effects of vorozole on DMBA-induced mammary tumors in female SD rats.
• To investigate the impact of vorozole on tissue insulin-like growth factor I (IGF-I) levels within these tumors.
• To elucidate the mechanism of action of vorozole in this rat mammary tumor model.

Main Methods:

• Female SD rats with DMBA-induced mammary tumors were treated with vorozole at doses of 0.25, 1.0, and 4.0 mg/kg/day orally for 28 days.
• Tumor size was measured weekly over the 4-week treatment period.
• Tissue samples from DMBA-induced tumors were analyzed for insulin-like growth factor I (IGF-I) concentrations.

Main Results:

• Vorozole treatment resulted in significant tumor size regression across all tested doses compared to the control group.
• Tumor regression was observed consistently at 1, 2, 3, and 4 weeks post-treatment initiation.
• A dose-dependent decrease in tissue IGF-I levels was noted in the DMBA-induced tumors of vorozole-treated rats.

Conclusions:

• Vorozole demonstrates significant efficacy in reducing the size of DMBA-induced mammary tumors in rats.
• The observed anti-tumor effect of vorozole is associated with a dose-dependent reduction in tumor tissue IGF-I.
• These findings highlight vorozole's therapeutic potential and its mechanism involving IGF-I modulation in mammary tumor treatment.